Article
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
Oncotarget - 2 Aug 2016
Kaibori Masaki, Sakai Kazuko, Ishizaki Morihiko, Matsushima Hideyuki, De Velasco Marco A, Matsui Kosuke, Iida Hiroya, Kitade Hiroaki, Kwon A-Hon, Nagano Hiroaki, Wada Hiroshi, Haji Seiji, Tsukamoto Tadashi, Kanazawa Akishige, Takeda Yutaka, Takemura Shigekazu, Kubo Shoji, Nishio Kazuto
Abstract excerpt
The multi-kinase inhibitor sorafenib is clinically approved for the treatment of patients with advanced hepatocellular carcinoma (HCC). We previously reported that fibroblast growth factor 3 and 4 (FGF3/FGF4) amplification is a predictor of a response to sorafenib. This study aims to analyze the relationship between FGF-FGF receptor (FGFR) genetic alterations and the response to sorafenib. Formalin-fixed,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.